Advanced Lipid Management

Work through ASCVD risk stratification and lipid-lowering therapy selection, from statin initiation to non-statin add-on decisions.

Practice this in the app More Cardiology tracks

What this track covers

This track covers lipid management from initial cardiovascular risk assessment through advanced therapy decisions. It addresses statin selection and intolerance, non-statin options including ezetimibe and PCSK9 inhibitors, and considerations for patients with familial hypercholesterolemia, elevated triglycerides, or elevated Lp(a).

What you will practice

Estimate ASCVD risk and identify risk-enhancing factors
Choose statin intensity based on patient risk category
Work through options for statin-associated muscle symptoms
Decide when to add ezetimibe or a PCSK9 inhibitor
Recognize patterns suggesting familial hypercholesterolemia or elevated Lp(a)

Simulator scenario

A patient with a strong family history of early heart disease and a very high LDL-C presents for a lipid evaluation, requiring risk assessment and a stepwise treatment plan.

Board question topics

ASCVD risk estimation and risk-enhancing factors
Statin intensity and intolerance management
Non-statin therapy sequencing
Familial hypercholesterolemia recognition

Ask the tutor

What does current guidance say about when to add a PCSK9 inhibitor after statin and ezetimibe?Opens the tutor · answers cite their sources How do I evaluate a patient who says they can't tolerate any statin?Opens the tutor · answers cite their sources What risk-enhancing factors should push me toward earlier treatment in a borderline-risk patient?Opens the tutor · answers cite their sources

The tutor only answers from licensed sources (FDA prescribing information, public guidelines and our own material) and says when it has none. Educational use only, never patient-specific advice.

Free during the beta. Sign in with your email, no password.

Start free